Fortrea Holdings (FTRE) Change in Accured Expenses (2022 - 2026)
Fortrea Holdings (FTRE) posted Change in Accured Expenses of -$43.4 million for Q1 2026, down 291.19% on a QoQ basis from $22.7 million in Q4 2025, and down 60.15% year-over-year from -$108.9 million in Q1 2025.
Fortrea Holdings (FTRE) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Fortrea Holdings' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$43.4 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 60.15% year-over-year to -$43.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.8 million (down 351.28% YoY) and the FY2025 annual result came in at $6.5 million, up 30.0% from the prior year.
- Change in Accured Expenses was -$43.4 million for Q1 2026 at Fortrea Holdings, down from $22.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $80.3 million in Q2 2023 and bottomed at -$65.1 million in Q1 2023.
- A 5-year average of -$3.5 million and a median of -$20.7 million in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses slumped 96.26% — and 2025, when it surged 746.67%.
- Fortrea Holdings' Change in Accured Expenses stood at -$22.7 million in 2022, then surged by 253.3% to $34.8 million in 2023, then jumped by 39.94% to $48.7 million in 2024, then slumped by 53.39% to $22.7 million in 2025, then slumped by 291.19% to -$43.4 million in 2026.
- Business Quant data shows FTRE's Change in Accured Expenses at -$43.4 million in Q1 2026, $22.7 million in Q4 2025, and -$14.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Fortrea Holdings | 1.84 Bn | 1.69 Bn | 123.60 Mn | -43.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.40 Mn |
| Mar 31, 2026 | -43.40 Mn |
| Dec 31, 2025 | 22.70 Mn |
| Dec 31, 2025 | 22.70 Mn |
| Sep 30, 2025 | -14.50 Mn |
| Sep 30, 2025 | -14.50 Mn |
| Jun 30, 2025 | 25.40 Mn |
| Jun 30, 2025 | 25.40 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | 48.70 Mn |
| Dec 31, 2024 | 48.70 Mn |
| Sep 30, 2024 | -20.70 Mn |
| Sep 30, 2024 | -20.70 Mn |
| Jun 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 3.00 Mn |
| Mar 31, 2024 | -26.00 Mn |
| Mar 31, 2024 | -26.00 Mn |
| Dec 31, 2023 | 34.80 Mn |
| Dec 31, 2023 | 34.80 Mn |